{
Helen Torley

People

}
biontech expands oncology focus with biotheus acquisition and promising pipeline
In 2024, BioNTech is set to enhance its oncology focus with the acquisition of Biotheus, expanding its bispecific antibody expertise and production capacity. The company reported strong Q3 results with EUR 1.2 billion in sales, driven by COVID-19 vaccines, while long-term growth hinges on its oncology pipeline, which includes over 32 clinical trials. Meanwhile, Evotec and Vidac Pharma are also making strides in cancer research, with Evotec emphasizing innovative partnerships and Vidac securing a key patent for its unique cancer therapies.
kapitalerhoehungen.de
Euro United States Dollar BioNTech SE DEU USA CHN Helen Torley Show more
Healthcare, Market Report
06:00 02.12.2024
halozyme withdraws acquisition bid for evotec amid independence stance
Halozyme Therapeutics Inc. has withdrawn its bid to acquire German drug developer Evotec SE for €11 per share, citing Evotec's reluctance to engage in discussions about a potential merger. The bid, which implied a valuation of €2.0 billion, was rejected as Evotec aims to maintain its independence, according to Halozyme's CEO Helen Torley.
Bloomberg.com
Euro Evotec SE Halozyme Therapeutics, Inc. DEU Helen Torley
Finance & Economy, Press Release
14:49 22.11.2024
halozyme withdraws evotec buyout bid following lack of interest
Halozyme has withdrawn its bid to acquire Evotec after the latter showed no interest in negotiations, despite a proposed valuation of €2 billion. Meanwhile, Neurogene reported the death of a patient in a gene therapy trial for Rett syndrome, linked to known risks of the treatment. In other news, Argenx is advancing its drug efgartigimod for myositis, while Kyowa Kirin has agreed to pay Kura Oncology $330 million for rights to an experimental leukemia drug.
BioPharma Dive
United States Dollar Euro Neurogenesis, Inc. Kyowa Kirin Co., Ltd. Evotec SE Kura Oncology, Inc. Halozyme Therapeutics, Inc. Triton Argenx USA Patrizia Cavazzoni Douglas C Throckmorton Helen Torley Show more
Healthcare, News Article
01:00 22.11.2024
halozyme plans cash takeover of evotec for 2 billion euros
Halozyme Therapeutics Inc. plans to finance its proposed €2 billion ($2.1 billion) takeover of Germany’s Evotec SE entirely in cash, as stated by CEO Helen Torley. She emphasized that no equity will be used, and despite taking on some debt, the company expects to quickly reduce its leverage to two times after the deal closes.
Bloomberg.com
Euro Halozyme Therapeutics, Inc. Evotec SE USA Helen Torley
Finance & Economy, Press Release
23:24 17.11.2024
Trending
Subcategory:
Cryptocurrency Markets Stock Market Updates Cryptocurrency Trends Corporate Responsibility & ESG Market Sentiment Analysis Central Bank Actions Decentralized Finance (DeFi) Innovations Cryptocurrency & Blockchain Regulations Banking Regulations Tokenomics and Crypto Economics Cryptocurrency Regulations Anti-Money Laundering (AML) Regulations Market Analysis and Predictions Funding Rounds & Investments Mergers & Acquisitions Cryptocurrency Developments SEC & Financial Compliance Inflation Rates & CPI Data Real Estate Investments Shareholder Activism
Countries:
USA CHE JPN AUS CAN IND GBR DEU AUT CHN HKG RUS LIE SAU BHR FRA ARG COL FIN NLD
Companies:
Coinbase Global, Inc. Ripples USD Solana USD BlackRock, Inc. Ethereum USD Credit Suisse Real Estate Fund Siat NVIDIA Corporation Cardano USD Tesla, Inc. Apple Inc. MicroStrategy Incorporated Amazon.com, Inc. Sumitomo Corp Google Inc. Bitwise Bitcoin ETF Chainlink USD Palantir Technologies Inc. Tether USDt CNY VAT Group AG Northern Star Resources Ltd
Currencies:
United States Dollar Euro Swiss Franc Japanese Yen Australian Dollar Canadian Dollar Colombian Peso Singapore Dollar Indian Rupee
People:
Ali Martinez Donald Trump Michael J. Saylor Elon Musk Karin Keller-Sutter Charles Hoskinson Bill Gates Fred Thiel Jack Dorsey Jacob King Brian Armstrong Aaron Green Gary Gensler Ueli Maurer Mario Nawfal Alan Santana Richard Schueler Roger J. Hamilton Steven Rossi Jane Dietze

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.